|
Management of Antimicrobial Adverse Effects by a Full-Time Pharmacist at an Antimicrobial Stewardship Team and Their Outcomes
Masahiro TAKADA1)2), Keitaro OMORI3), Mika SHINGAI1), Kanami HOSHIKAWA2) and Takeshi SUDO1)4) 1)Division of Infection Control and Prevention, National Hospital Organization Kure Medical Center, 2)Division of Pharmacy, National Hospital Organization Kure Medical Center, 3)Department of Infection Diseases, Hiroshima University Hospital, 4)Department of Surgery, National Hospital Organization Kure Medical Center
To evaluate how the involvement and outcomes of antibiotic-associated adverse drug events (ADEs) changed as a result of full-time pharmacists in the Antimicrobial Stewardship Team (AST), we investigated the "response to ADEs" as part of AST interventions. This single-center cohort study compared process and outcome measures between two periods: pre-introduction from April 2021 to August 2022 and post-introduction from September 2022 to January 2024 of full-time AST pharmacists, among hospitalized patients. The number of patients responding to ADEs in the AST intervention increased significantly from 1.9% (5/264 patients) in the pre-introduction group to 7.2% (67/936 patients) in the post-introduction group (p = 0.002). Grade 1 ADEs increased from 0 cases pre-introduction to 10 cases post-introduction. The variety of ADEs intervened increased from 3 to 18. The most frequent intervened ADEs were Clostridioides difficile infection 19% (14: 0 in pre-introduction, 14 in post-introduction), skin disorders 15% (11: 2 in pre-introduction, 9 in post-introduction), and eosinophilia 12% (9: 0 in pre-introduction, 9 in post-introduction). In terms of clinical outcomes, 87% of ADEs cases resulted in recovery (65: 5 in pre-introduction, 60 in post-introduction), and 90% were cured (53: 5 in pre-introduction, 48 in post-introduction), with no statistically significant differences in outcome rates between groups. Therefore, full-time employment of AST pharmacists is effective in increasing the number of patients responding to ADEs, as well as in detecting a variety of ADEs in mild cases, and in supporting the completion of treatment of infectious diseases.
Key words:antibiotic-associated adverse drug events, intervention, full-time pharmacist, outcome
e-mail:
takada.masahiro.gu@mail.hosp.go.jp
Received: February 20, 2025 Accepted: May 16, 2025
40 (4):182─189,2025
|